These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9254338)

  • 1. Postexposure treatment of HIV.
    Pinkerton SD; Holtgrave DR; Bloom FR
    N Engl J Med; 1997 Aug; 337(7):500-1. PubMed ID: 9254338
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
    Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
    Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use.
    Katz MH; Gerberding JL
    N Engl J Med; 1997 Apr; 336(15):1097-100. PubMed ID: 9091810
    [No Abstract]   [Full Text] [Related]  

  • 4. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study follows PEP for sexual exposures.
    AIDS Alert; 1998 Sep; 13(9):106-7. PubMed ID: 11365790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM; Tsevat J
    Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of preventing HIV infection after sexual exposure.
    Lindbloom EJ; Stevermer JJ
    J Fam Pract; 1998 Oct; 47(4):251-2. PubMed ID: 9789505
    [No Abstract]   [Full Text] [Related]  

  • 9. Postexposure prophylaxis after sexual exposure to HIV.
    Roland ME
    Curr Opin Infect Dis; 2007 Feb; 20(1):39-46. PubMed ID: 17197880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
    Pinkerton SD; Holtgrave DR; Bloom FR
    AIDS; 1998 Jun; 12(9):1067-78. PubMed ID: 9662204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postexposure treatment of HIV.
    Li RW; Wong JB
    N Engl J Med; 1997 Aug; 337(7):499-500; author reply 501. PubMed ID: 9254337
    [No Abstract]   [Full Text] [Related]  

  • 12. Post-exposure prophylaxis (PEP) after non-occupational risk of HIV infection.
    Kinghorn GR; Evans B; Nunn A; Darbyshire J; Adler MW; Carne CA
    Sex Transm Infect; 1998 Aug; 74(4):304. PubMed ID: 9924479
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV postexposure prophylaxis after sexual assault.
    Stevens L; Brown MA
    Nurse Pract Forum; 2001 Dec; 12(4):192-8. PubMed ID: 11889687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of HIV therapies in different economic worlds.
    Laurence J
    AIDS Read; 2001 May; 11(5):236-7. PubMed ID: 11392685
    [No Abstract]   [Full Text] [Related]  

  • 15. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure.
    Roland ME; Martin JN; Grant RM; Hellmann NS; Bamberger JD; Katz MH; Chesney M; Franses K; Coates TJ; Kahn JO
    J Infect Dis; 2001 Dec; 184(12):1608-12. PubMed ID: 11740738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effective HIV treatment for developing countries.
    Bull World Health Organ; 1999; 77(9):780. PubMed ID: 10534904
    [No Abstract]   [Full Text] [Related]  

  • 17. Durability of clinical responses to anti-HIV therapies.
    Laurence J
    AIDS Read; 2008 Mar; 18(3):120-1. PubMed ID: 18398977
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.
    Moatti JP; N'Doye I; Hammer SM; Hale P; Kazatchkine M
    Nat Med; 2003 Dec; 9(12):1449-52. PubMed ID: 14647513
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV antiretroviral postexposure prophylaxis: a cautionary note.
    Cohen MS; Kashuba AD; Gay C
    Clin Infect Dis; 2005 Nov; 41(10):1514-6. PubMed ID: 16231266
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of HIV post-exposure prophylaxis in France.
    Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
    AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.